Ramping up the drug pricing debate: Dueling bills and paying for health care infrastructure

Published date26 April 2021
Subject MatterMedicare,Medicaid,Prescription Drugs,Regulatory Agenda,Legislative Agendas,Critical Infrastructure Sectors,Medicare Part D,Healthcare Reform,Drug Pricing,Pharmaceutical Industry,Patient Access,Department of Health and Human Services (HHS),Medicaid Drug Rebate Program,Biden Administration
AuthorAlice Valder Curran,Samantha Marshall,Thomas Beimers,Ronald Wisor, Jr.,Ken Choe,Elizabeth Halpern,Stuart Langbein,Beth Roberts,James Huang,Melissa Bianchi,W. Boyd Jackson,James Deal,Mahmud Brifkani,Anna Weinstein,Cybil Roehrenbeck
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT